Incyte and Genesis Therapeutics are partnering to use artificial intelligence (AI) to research, discover, and develop small molecule treatments. The collaboration could generate up to $620 million for Genesis. The companies will use Genesis’s AI platform, GEMS, for their research. Incyte has exclusive rights for potential clinical development and commercialization of the products developed through the collaboration. The companies have not disclosed the targets they plan to develop.
400+ SAP NetWeaver Devices Vulnerable to 0-Day Attacks that Exploited in the Wild
Shadow Servers have identified 454 vulnerable SAP NetWeaver systems affected by a critical zero-day flaw, CVE-2025-31324, allowing unauthenticated file uploads and potential system compromise. Discovered
